Memantine

• Description:

  Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD) [1][2][3].

• UNSPSC:

  12352211

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  IGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/memantine.html

• Concentration:

  10mM

• Purity:

  99.89

• Solubility:

  DMSO : 10 mg/mL (ultrasonic)

• Smiles:

  N[C@]12C[C@@]3 (C) C[C@] (C2) (C) C[C@@H] (C1) C3

• Molecular Formula:

  C12H21N

• Molecular Weight:

  179.30

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Marotta G, et al. Memantine Derivatives as Multitarget Agents in Alzheimer's Disease. Molecules. 2020;25 (17) :4005. Published 2020 Sep 2. |[2]Pinho J, et al. Enhanced LTP in aged rats: Detrimental or compensatory?. Neuropharmacology. 2017;114:12-19. |[3]Moriguchi S, et al. Memantine Improves Depressive-like Behaviors via Kir6.1 Channel Inhibition in Olfactory Bulbectomized Mice. Neuroscience. 2020;442:264-273.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Biomedicines. 2022 Sep 22;10 (10) :2358.|bioRxiv. 2025 March 02.|Int J Mol Sci. 2024 Nov 19;25 (22) :12404.|Pharmacol Res Perspect. 2021 Oct;9 (5) :e00879.|Biomark Res. 2023 Aug 8;11 (1) :74.|Folia Neuropathol. 2023;61 (1) :25-36.|J Nanobiotechnology. 2025 Jun 16;23 (1) :445.|Neurochem Res. 2018 Oct;43 (10) :2008-2015.|Neuropharmacology. 2021 Feb 15:184:108443.

• CAS Number:

  19982-08-2